Aratana therapeutics granted first FDA approval of GALLIPRANT
Aratana Therapeutics, Inc., a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced the Food and Drug Administration's Center for Veterinary Medicine (CVM) approved GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs.
[adsense:336x280:8701650588]
Galliprant is expected to be available to veterinarians in fall 2016.
[adsense:468x15:2204050025]
Galliprant is a prostaglandin E2 (PGE2) EP4 receptor antagonist (PRA), a non-cyclooxygenase inhibiting, non-steroidal and anti-inflammatory drug. Galliprant blocks PGE2-elicited pain and inflammation.